BMO Capital analyst Matthew Luchini maintained a Buy rating on Arvinas Holding Company (NASDAQ:ARVN) on Tuesday, setting a price target of $116, which is approximately 36.89% above the present share price of $84.74.
Luchini expects Arvinas Holding Company to post earnings per share (EPS) of -$1.03 for the fourth quarter of 2021.
The current consensus among 9 TipRanks analysts is for a Strong Buy rating of shares in Arvinas Holding Company, with an average price target of $121.56.
The analysts price targets range from a high of $135 to a low of $110.
In its latest earnings report, released on 06/30/2021, the company reported a quarterly revenue of $5.54 million and a net profit of -$51.88 million. The company's market cap is $4.46 billion.
According to TipRanks.com, BMO Capital analyst Matthew Luchini is currently ranked with 2 stars on a 0-5 stars ranking scale, with an average return of 2.3% and a 37.60% success rate.
Arvinas, Inc. is a biopharmaceutical company, which engages in the discovery, development and commercialization of therapies to degrade disease-causing proteins. Its lead products include ARV-110 and ARV-471. The company was founded in February 2013 and is headquartered in New Haven, CT.